Related Experiment Videos
Targeted therapy for lung cancer
Rajesh Kukunoor1, Jigar Shah, Tarek Mekhail
1Taussig Cancer Center, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Abstract:
Lung cancer remains the leading cause of death in men and women in the United States. This status is attributed to late diagnosis and lack of effective chemotherapy for metastatic lung cancer. Understanding of the mechanism by which mutated genes confer a neoplastic phenotype on cells has resulted in the development of many potential targeted cancer therapies. This article briefly discusses the work being done with some of these targeted agents in the treatment of lung cancer.
Insights
Lung cancer is a leading cause of death, often due to late diagnosis. Targeted therapies offer new hope for treating metastatic lung cancer by targeting mutated genes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung cancer is the primary cause of cancer-related mortality in the United States.
- Late diagnosis and limited chemotherapy options for metastatic disease contribute to poor outcomes.
- Advances in understanding gene mutations in cancer have spurred the development of targeted therapies.
Purpose of the Study:
- To review the current landscape of targeted therapy development for lung cancer.
- To discuss specific targeted agents being investigated for lung cancer treatment.
Main Methods:
- Literature review of targeted agents in lung cancer research.
- Discussion of mechanisms of action for selected targeted therapies.
Main Results:
- Several targeted agents show promise in preclinical and clinical studies.
- Targeted therapies aim to inhibit specific molecular pathways driving cancer growth.
Conclusions:
- Targeted therapies represent a significant advancement in lung cancer treatment.
- Further research is crucial to optimize the efficacy and application of these agents.